Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology ...
Eupraxia Pharmaceuticals Reports Q3 Progress and Funding
Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals reported advances in its clinical trials and financial ...
Eupraxia Pharmaceuticals Secures C$44.5 Million Investment
Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has successfully raised C$44.5 million through a ...
The Victoria Advocate13d
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
VICTORIA, BC, Oct. 28, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
Nasdaq26d
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
VICTORIA, BC, Oct. 15, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology ...
Morningstar5d
Eupraxia Pharmaceuticals Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Nasdaq9d
Eupraxia Pharmaceuticals Secures C$44.5 Million Investment
Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has successfully raised C$44.5 million through a non-brokered private placement of preferred shares to support ...